ArticleExperimental and therapeutic medicine2016
Clinical characteristics of drug-induced liver injury and related risk factors.
Article in Experimental and therapeutic medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 56 citations in OpenAlex.
- Article
- Risk factors related to significant hepatic inflammation in patients with acute drug-induced liver injury.iLIVER · 2024Article
- Exploring Individual Variability in Drug-Induced Liver Injury (DILI) Responses through Metabolomic Analysis.International journal of molecular sciences · 2024Article
- InterDILI: interpretable prediction of drug-induced liver injury through permutation feature importance and attention mechanism.Journal of cheminformatics · 2024Article
- Unexpected Drug-Induced Liver Injury Associated With MenoFit: A Synbiotic Menopause Supplement.ACG case reports journal · 2023Article
- Acetaminophen-Induced Hepatotoxicity in Obesity and Nonalcoholic Fatty Liver Disease: A Critical Review.Livers · 2023Article
- Analysis of Risk Factors and Protective Strategies for Tube Blockage in Patients with Drug-Induced Liver Failure Based on Artificial Liver Therapy.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Liver Damage and microRNAs: An Update.Current issues in molecular biology · 2022Review
- Identification of New Toxicity Mechanisms in Drug-Induced Liver Injury through Systems Pharmacology.Genes · 2022Article
- Incidence and Temporal Trend of Antituberculosis Drug-Induced Liver Injury: A Systematic Review and Meta-Analysis.Journal of tropical medicine · 2022Article
- Analytical and Omics-Based Advances in the Study of Drug-Induced Liver Injury.Toxicological sciences : an official journal of the Society of Toxicology · 2021Review
- Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection.Internal medicine (Tokyo, Japan) · 2021Article
- Overview of drug induced liver injury in Brazil: What is the role of public health policy on the evidence?World journal of gastrointestinal pharmacology and therapeutics · 2021Article
- Characteristics of Drug-Induced Liver Injury in Northeast China: Disease Spectrum and Drug Types.Digestive diseases and sciences · 2020Article
- Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis.Medicines (Basel, Switzerland) · 2020Review
- Single-nucleotide polymorphisms ofWorld journal of gastroenterology · 2020Article
- A Change in Bile Flow: Looking Beyond Transporter Inhibition in the Development of Drug-induced Cholestasis.Current drug metabolism · 2019Review
- Influence Factors on the Hepatotoxicity ofEvidence-based complementary and alternative medicine : eCAM · 2019Review
- Metabolic Comorbidities and Risk of Development and Severity of Drug-Induced Liver Injury.BioMed research international · 2019Review
- Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced liver injury (DILI) is often undiagnosed or misdiagnosed clinically because of diagnostic difficulties caused by lack of laboratory-specific serological markers. In this study, we comprehensively assessed the clinical characteristics, laboratory indices, hepatotoxic drugs, risk factors and outcomes concerning DILI, and explored the similarities in mechanisms between Chinese and Western drug-induced DILI. Patients with a first diagnosis of DILI and a Roussel Uclaf Causality Assessment Method (RUCAM) score >3 points were enrolled for systematic retrospective study. Their clinical characteristics, clinical classification, risk factors, laboratory indices, hepatotoxic drugs and outcomes were analyzed. Cholestatic patients had the highest alkaline phosphatase (ALP) and prothrombin time activity (PTA) levels (P<0.05). Patients with medication time ≥30 days had significantly higher positive rate of autoantibodies than those with medication time <30 days. Odds ratio values for DILI-related factors such as hepatobiliary diseases, immune dysfunction, diabetes, hypertension, chronic alcohol consumption and age ≥45 years were 6.552, 6.130, 3.774, 2.801, 2.002 and 1.838, respectively. Pathogeneses of Chinese and Western drug-induced DILI may be substantially the same. DILI accompanied with autoantibody positivity may indicate severe liver injury outcome. Hepatobiliary diseases, diabetes and hypertension are likely to increase drug susceptibility, and more prone to cause liver injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.